
Stereotaxis, Inc.
AMEX•STXS
CEO: Dr. David Leo Fischel C.A.I.A., C.F.A., C.P.A., M.B.A.
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Listing Date: 2004-08-12
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane, full-power x-ray system, including c-arm, powered table, motorized boom, and monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. It markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with MAGiC catheter for cardiac ablation procedures. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri.
Contact Information
710 North Tucker Boulevard, Suite 110, Saint Louis, MO, 63101, United States
314-678-6100
Market Cap
$249.18M
P/E (TTM)
-10.4
12
Dividend Yield
--
52W High
$3.59
52W Low
$1.54
52W Range
Rank58Top 85.6%
2.3
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q3 2025 Data
Revenue
$7.46M-18.83%
4-Quarter Trend
EPS
-$0.07-7.77%
4-Quarter Trend
FCF
$0.00-100.00%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Nine Months Revenue Growth Nine months total revenue reached $23.74M, increasing 15% driven by full year impact of acquired disposable sales.
Common Stockholder Loss Narrowed Net loss attributable to common stockholders narrowed to $17.07M, improving from $17.51M prior nine-month period.
Q3 Gross Margin Expansion Q3 Gross Margin rose to 55% from 45% last year, due to favorable shift in product mix towards disposables.
Financing Activities Provided Cash Secured $7.81M net cash from financing activities, primarily driven by July 2025 registered direct equity offering proceeds.
Risk Factors
Macroeconomic and Supply Chain Macro factors, supply chain issues, and inflation continue to pressure operations, potentially impacting product availability.
G&A Expense Driven Higher G&A expenses rose 13% to $13.7M, primarily driven by contingent consideration revaluation expense recognized in earnings.
Fluid Global Tariff Environment Fluid global tariff environment, especially US-China, could materially affect cost structure and gross margins if reinstated.
Future Capital Needs Risk Existing cash may not suffice; future financing may be required, potentially dilutive to current common stockholders.
Outlook
Advance Regulatory Adoption Plans to advance adoption of robotic systems in markets where regulatory clearance has been recently received or is pending.
Continued Operating Losses Expected Expect additional operating losses in remainder of 2025 while funding development, commercialization, and marketing initiatives.
APT Integration Focus Management focused on integrating APT business, minimizing complexity, and realizing strategic benefits post-acquisition completion.
ATM Program Funding Available $50.0M ATM Program remains available for working capital and accelerated commercialization pipeline funding needs.
Peer Comparison
Revenue (TTM)
NEO$709.16M
$130.10M
$101.90M
Gross Margin (Latest Quarter)
92.9%
60.5%
58.4%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| NEO | $331.49M | -2.9 | -13.0% | 29.8% |
| QTRX | $302.69M | -3.1 | -30.5% | 9.0% |
| STXS | $249.18M | -10.4 | -249.4% | 12.2% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
5.6%
Steady Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
25%
Cash Flow Needs Attention
Research & Insights
Next earnings:Mar 2, 2026
EPS:-$0.06
|Revenue:-
Reports
All Years
Form 10-Q - Q3 2025
Period End: Sep 30, 2025|Filed: Nov 12, 2025|Revenue: $7.46M-18.8%|EPS: $-0.07-7.8%MissForm 10-Q - Q2 2025
Period End: Jun 30, 2025|Filed: Aug 13, 2025|Revenue: $8.80M+95.4%|EPS: $-0.05-35.3%BeatForm 10-Q - Q1 2025
Period End: Mar 31, 2025|Filed: May 13, 2025|Revenue: $7.47M+8.6%|EPS: $-0.07+20.5%BeatForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Mar 14, 2025|Revenue: $26.92M+0.5%|EPS: $-0.30-11.1%MissForm 10-Q - Q3 2024
Period End: Sep 30, 2024|Filed: Nov 14, 2024|Revenue: $9.20M+17.9%|EPS: $-0.08+9.7%MissForm 10-Q - Q2 2024
Period End: Jun 30, 2024|Filed: Aug 14, 2024|Revenue: $4.50M-42.7%|EPS: $-0.07+19.0%MissForm 10-Q - Q1 2024
Period End: Mar 31, 2024|Filed: May 15, 2024|Revenue: $6.88M+5.1%|EPS: $-0.06-9.7%BeatForm 10-K - FY 2023
Period End: Dec 31, 2023|Filed: Mar 8, 2024|Revenue: $26.77M-4.9%|EPS: $-0.27-3.8%Miss